Skip to main content
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2022 Dec 15;13:1042762. doi: 10.3389/fphar.2022.1042762

Corrigendum: Xiaoyaosan alleviates hippocampal glutamate-induced toxicity in the CUMS rats via NR2B and PI3K/Akt signaling pathway

Xueming Zhou 1,2,, Chenyue Liu 1,, Yueyun Liu 1, Qingyu Ma 3, Xin Zhao 1, Youming Jiang 1, Xiaojuan Li 3,*, Jia-Xu Chen 1,3,*
PMCID: PMC9800046  PMID: 36588727

In the published article, there was an error in Figures 5A, 8A as published. The wrong images were used in Figure 5A at the vehicle (W) and vehicle (D) group as well as Figure 8A. The correct version of the figure shows below. The corrected Figures 5, 8 and its caption appear below.

FIGURE 5.

FIGURE 5

Xiaoyaosan elevates the expression of MAP2 in the hippocampal CA1 region of CUMS rats (A, original magnifification, ×200) Xiaoyaosan and Xiaoyaosan + Ly294002 promoted MAP2 expression in the CUMS rats. The green color represents MAP2 staining, and the blue color represents nuclear staining (C) Representative images and western blot analysis (D) of western blot assay showing the relative expression of MAP2 (B) Level of MAP2 mRNA in the hippocampal CA1 area of the rats in the treatment and control groups. All data are expressed as the mean ± SD. # p < 0.05 compared to the control group; * p < 0.05 compared to the vehicle (W) group; p < 0.05 compared to the Ly294002 group, n = 6.

FIGURE 8.

FIGURE 8

Xiaoyaosan elevates the expression of P-AKT/AKT in the hippocampal CA1 region of CUMS rats P-AKT/AKT in the hippocampal CA1 region of CUMS rats (A) Representative micrographs of immunohistochemical staining (sections were counterstained with hematoxylin; original magnifification, ×200) and (B) quantitative analysis showing the expression of P-AKT in the hippocampal CA1 region (C). Representative images and western blot analysis (D) of western blot assay showing the relative expression ratio of P-AKT/AKT in the hippocampal CA1 region. All data are expressed as the mean ± SD. # p < 0.05 compared to the control group; * p < 0.05, compared to the vehicle (W) group; p < 0.05 compared to the Ly294002 group, n = 6.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES